Dong-A ST Launches Stellar Biosimilar Imuldosa in the U.S., an Autoimmune Disease Treatment
Aug 19, 2025
|
Stella, an autoimmune disease treatment developed by Janssen, is mainly used to treat plate psoriasis, psoriasis arthritis, Crohn's disease, and ulcerative colitis. Globally, the company recorded approximately $21.552 billion (accumulated sales for IQVIA 2024).
Stellar's biosimilar, Imuldosa, has been jointly developed by Dong-A Socio Holdings and Meiji Sei-Ka Pharma since 2013, and in July 2020, the rights to develop and commercialize were transferred to Dong-A ST for efficient global projects, and Dong-A ST and Meiji Sei-Ka Pharma jointly developed it. In July 2021, it signed a global license-out agreement with multinational pharmaceutical company Intas and Immuldo Corp. Intas is commercializing ImmulDosa through Accord Biopharma in the United States and its affiliates worldwide, including Accord Healthcare in Europe, the United Kingdom and Canada. Immuldo has been launched in a total of 14 countries, including Germany, the UK, and Spain, and has obtained product licenses in MENA regions such as Saudi Arabia, Qatar, and the United Arab Emirates.
An official from Dong-A ST said "Imul-Dosa is being launched in the U.S. following Europe, accelerating its entry into the global market."We will do our best to make this an effective treatment option for patients around the world."."
This article was translated by Naver AI translator.
